PubMed Health⌕ Search

Biomedical subjects

F Heinemann

Publications and source records attributed to F Heinemann.

18 recordsLinked to original sources
PubMed1999

[Second malignancies after the therapy of Hodgkin's disease: the Freiburg collective 1940 to 1991].

AIM: To quantify the risk of second malignancies in patients with Hodgkin's disease treated at the Department of Radiotherapy, University Clinic Freiburg, with the object of comparing this risk with the international experience and as a contribution to the discussion about future treatment. PATIENTS AND METHODS: Second malignancies were reviewed in 1,588 patients treated for Hodgkin's disease between 1940 and 1991. Treatment consisted of involved or extended field radiotherapy as a single modality or in combination with chemotherapy. Before the early 1970's, chemotherapy used (sequential) monodrug regimens. The mean follow-up was 8.3 years. The cumulative risk was calculated using the Kaplan-Meier method and related to the risk of a normal population taken from epidemiological data of the National Cancer Institute. An estimate of radiation dose at the site of origin of the second malignancy was obtained from representative measurements employing an Alderson phantom. RESULTS: After 5, 10, 15 and 20 years the cumulative risk for all malignancies was 1.5%, 4.2%, 9.4% and 21%, respectively; for solid tumors it came to 1.2%, 3.1%, 7.9% and 19%; for non-Hodgkin lymphoma (NHL) the risk amounted to 0.1%, 0.9%, 1.4% and 1.9%; and for leukemia it was 0.1%, 0.3%, 0.6% and 0.6%. For the same time points the relative risk for all malignancies was calculated to be 1.1, 1.4, 1.8 and 2.5; for solid tumors it came to 1.0, 1.1, 1.6 and 2.5; for NHL it amounted to 3.3, 11.8, 9.3 and 8.0; and for leukemia it was 3.3, 3.1, 3.4 and 2.1. For combinations of radiotherapy and chemotherapy the risk for second malignancies was highest in patients receiving ABVD any time during their treatment. 51% of the second malignancies were located infield, 22% at the field border and 27% outfield. In those cases for which the cause of death was known, Hodgkin's disease accounted for 79% followed by second malignancies accounting for 8%. The results obtained in Freiburg fell within the range reported in international publications. CONCLUSION: The increased incidence of second malignancies in cured Hodgkin's patients is along-term risk making regular follow-up mandatory. Although part of the second malignancies are unrelated to therapy, there is a need to carefully collect the data from patients treated according to new protocols in order to detect any changes in the number or kind of second malignancies in due time. This may well lead to a reassessment of therapeutic concepts.

Adult↗
PubMed1999

[Folk medical practices in psychiatric patients of Turkish origin in Germany].

The treatment of Turkish patients is peculiar due to differences of socio-cultural background and speech. Magic conceptions of pathogenesis and nosogeny have a broad acceptance in a part of population. Magic faith healers, Hocas, are authorities to be consulted for treatment. In ritual acts they intend to stave off noxious influences and to strengthen the healing power with sacred formulas and through powerful objects. To investigate the importance, utilisation and attitude towards the Hocas of Turkish psychiatric patients living in Germany we conducted an interview with 55 psychiatric inpatients. Our findings were a reduced importance of Hocas due to influences of the Western culture and modern medicine. "Folk" medicine is still important for patients with psychic disorders and is used parallel to modern medical facilities.

Adult↗
PubMed1998

Neuroleptic malignant syndrome under treatment with antidepressants? A critical review.

Neuroleptic malignant syndrome (NMS) is a rare complication of treatment with neuroleptics. The pathophysiology is not fully known. A dopaminergic transmission block in the basal ganglia and hypothalamus is thought to be the pathophysiological mechanism of NMS. Several cases of NMS have been reported, precipitated by medication without a direct effect on the dopaminergic system. This Medline analysis concerns 23 cases of antidepressant-induced NMS reported in the literature with the differing pathophysiological hypotheses on the precipitation of NMS. The results indicate no hard evidence of an antidepressant-evoked NMS. However, various hypotheses assuming an disturbed balance of the dopaminergic and non-dopaminergic system may be relevant in animal studies, but are without clinically relevant proof presently. An antidepressant-induced NMS is a very rare complication on the basis of pretreatment with neuroleptics causing chronic dopamine blockade and elevated plasma level of neuroleptics due to comedicated antidepressants.

Antidepressive Agents↗
PubMed1997

[Paroxetine-induced neuroleptic malignant syndrome].

We report on a 22-year-old schizophrenic patient who attempted suicide and suffered an epidural hemorrhage. 16 days after the neurosurgical operation. After several weeks of treatment with promethazine, 1 day after intake of paroxetin he partially lost consciousness and developed extrapyramidal symptoms and vegetative disorders. Hyper-Ck-aemia up to 680 U/l was observed. Malignant neuroleptic syndrome (MNS) was diagnosed, which led to withdrawal of paroxetin and promethazine. He was put on dantamacrine and amantadine until the symptoms resolved. To date there have been few reports on MNS under tricyclic antidepressants and selective serotonin inhibitors. The influence of the central serotonergic system on the pathophysiology of MNS is discussed.

Adult↗
PubMed1997

[Neuroleptic malignant syndrome from treatment with antidepressives].

The neuroleptic malignant syndrome (NMS) is a rare complication in the treatment of neuroleptics. The pathophysiology is not fully known. A dopaminergic transmission block in the basal ganglia and the hypothalamus is thought to be the pathophysiological mechanism of NMS. There are some findings against the single role of dopamine receptor blockade: NMS is rare under neuroleptic treatment, although a strong dopamine receptor blockade is found even with a low dosis of neuroleptics. NMS can develop even after longterm treatment with neuroleptics and is not improved by dopamine agonists within the expected period. NMS may even develop when neuroleptics are reduced. Several cases have been reported of NMS precipitated by medication without a direct effect on dopaminergic system. Only rare case reports describe NMS under antidepressants. We report on all cases of NMS associated with antidepressants and present the different pathophysiological hypotheses on the precipitation of NMS.

Adult↗
PubMed1996

Hepatotoxic side-effect of clomethiazole.

We report on a patient with a history of alcoholism who developed hyperbilirubinemia induced by treatment with clomethiazole during two hospitalizations. After discontinuation of clomethiazole symptoms of cholestasis improved. Clomethiazole is a thiazole analogon and is chemically related to thiamine (vitamin B1). It can be administered as tablets, capsules, mixtures, and a 0.8% solution. Because of its sedative, hypnotic, and anti-convulsive effects it is used in the treatment of alcoholic delirium.

Alcohol Withdrawal Delirium↗
PubMed1996

[Language regression to the mother tongue in polyglot patients with acute psychosis].

Three bilingual patients with schizophrenia are presented, who spoke almost exclusively in their native language during acute episodes of psychosis. Normal use of the foreign language, German, was again possible after remission of the acute symptoms. This phenomenon of regression is similar to speech disorders in patients with aphasia and is discussed with reference to recent biological findings.

Acute Disease↗
PubMed1996

[Panic attacks with cycloleptic course--differential diagnostic considerations in differentiating panic disorder from epileptic anxiety attacks].

This paper reports on a patient suffering from panic-attacks. A therapy with antidepressants and benzodiazepines was ineffective. The panic-attacks had a short duration and a cycloleptic course. Under the treatment with carbamazepine panic attacks improved. The differential diagnosis of panic disorder and epileptic panic attacks is discussed.

Anticonvulsants↗
PubMed1994

[Tardive dystonia. A rare neuroleptic-induced disease picture].

This paper reports on a case of spasmodic torticollis after longterm treatment with neuroleptics. This form of dystonia is called tardive dystonia to distinguish it from tardive dyskinesia. Its pathophysiology is unknown. Pathological changes are described in the basal ganglia. Increased signal was found on magnetic resonance imaging on both sides of the basal ganglia reflecting structural lesions. These structural changes, together with neuroleptic medication, represent predisposing factors for the manifestation of tardive dystonia.

Basal Ganglia↗
PubMed1993

Endogenous superantigen expression controlled by a novel promoter in the MMTV long terminal repeat.

Endogenous superantigens are encoded by the open reading frame contained within the mouse mammary tumour virus long terminal repeat (MMTV LTR). Superantigen expression results in T-cell proliferation and, during early ontogeny, T-cell deletion. Here we identify a novel promoter located upstream of the previously described MMTV promoter. Transcripts from this promoter initiate within the U3 region of the MMTV LTR and splice to the acceptor for endogenous superantigen coding region. The novel U3 promoter is active in B lymphocytes, which are cognate antigen-presenting cells for endogenous superantigen, and is able to direct expression of superantigen in the absence of the previously described MMTV promoter.

Animals↗
PubMed1992

[PC-assisted planning and documentation of the surgical schedule].

A computer program for personal computers was developed to support and control the schedule in the operation theatre. With this program a great amount of operational and medical data will be recorded (e.g. the duration of operation and anesthesia, the number of operating rooms occupied, the personnel involved, the diagnosis and surgical therapy). The screen shows up-to-date information about the ongoing events. All data can be easily evaluated for different criteria. In a four years period the program presented has proved valuable for daily routine planning and documentation in a great operation unit.

Database Management Systems↗
PubMedDate not supplied

In vivo perivascular implantation of encapsulated packaging cells for prolonged retroviral gene transfer.

Long-term benefits of coronary angioplasty remain limited by the treatment-induced renarrowing of arteries, termed restenosis. One of the mechanisms leading to restenosis is the proliferation of smooth muscle cells. Therefore, proliferating cells of the injured arterial wall, which can be selectively transduced by retroviruses, are potential targets for gene therapy strategies. A direct single-dose therapeutic application of retroviral vectors for inhibition of cell proliferation is normally limited by too low transduction efficiencies. Encapsulated retrovirus-producing cells release viral vectors from microcapsules, and may enhance the transduction efficiency by prolonged infection. Primary and immortal murine and porcine cells and murine retrovirus-producing cells were encapsulated in cellulose sulphate. Cell viability was monitored by analysing cell metabolism. Safety, stability, transfer efficiency and extent of restenosis using capsules were determined in a porcine restenosis model for local gene therapy using morphometry, histology, in situ beta-galactosidase assay and PCR. Encapsulation of cells did not impair cell viability. Capsules containing retrovirus-producing cells expressing the beta-galactosidase reporter gene were implanted into periarterial tissue or a pig model of restenosis. Three weeks following implantation, beta-galactosidase activity was detected in the pericapsular tissue with a transduction efficiency of approximately 1 in 500 cells. Adventitial implantation of vector-producing encapsulated cells for gene therapy may, therefore, facilitate successful targeting of proliferating vascular smooth muscle cells, and allow stable integration of therapeutic genes into surrounding cells. The encapsulation of vector-producing cells could represent a novel and feasible way to optimize local retroviral gene therapy.

3T3 Cells↗